The US Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback